olmesartan has been researched along with everolimus in 1 studies
| Studies (olmesartan) | Trials (olmesartan) | Recent Studies (post-2010) (olmesartan) | Studies (everolimus) | Trials (everolimus) | Recent Studies (post-2010) (everolimus) |
|---|---|---|---|---|---|
| 841 | 185 | 554 | 5,631 | 1,289 | 4,579 |
| Protein | Taxonomy | olmesartan (IC50) | everolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 2 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0022 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Fujimoto, Y; Ishikawa, K; Kobayashi, Y; Miura, K; Nakayama, T; Sugimoto, K | 1 |
1 trial(s) available for olmesartan and everolimus
| Article | Year |
|---|---|
Protective effect of angiotensin II receptor blocker and calcium channel blocker on endothelial vasomotor function after everolimus-eluting stent implantation.
Topics: Acetylcholine; Aged; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug-Eluting Stents; Endothelium, Vascular; Everolimus; Female; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Tetrazoles; Vasoconstriction; Vasodilation | 2016 |